COVID-19 and thrombosis: Beyond a casual association.

COVID-19 and thrombosis: Beyond a casual association. Med Clin (Barc). 2020 May 11;: Authors: López Castro J PMID: 32446683 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research

Related Links:

This study aimed to investigate the role of COVID-19 associated coagulopathy (CAC) to preview and triage. Methods and Results: A cohort study was designed from government designated COVID-19 treatment center. CAC was defined as International Society on Thrombosis and Haemostasis (ISTH) score ≥2. Data from 117 patients COVID-19 were reviewed on admission.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Full Length Article Source Type: research
In this study, 12 thrombotic events occurred in 9 patients, including 4 cerebral infarctions, 7 acro-ischemia and 1 internal jugular vein thrombosis. The common abnormalities of routine coagulation tests included evelated D-Dimer level (100%), prolonged prothrombin time (73.7%) and hyperfibrinogenemia (73.7%). The median activities of natural anticoagulants including protein C, protein S and antithrombin were all below the normal range. Factor VIII activities were significantly above normal range (median value 307%, IQR 198 –441) in all patients. Factor V and factor VII activities were significantly lower in near-ter...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
We describe a series of three cases of aortic thrombi diagnosed by computerized tomography (CT) angiography in patients with confirmed SARS-CoV-2 infection.
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
(JAMA Network) This case report describes a patient with COVID-19 who developed late drug-eluting stent thrombosis.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
AbstractObjectivesTo determine if a specific immunomodulatory intervention reduces progression of COVID-19-related disease to organ failure or death, compared to standard of care (SoC).Trial designRandomised, parallel 3-arm (1:1:1 ratio), open-label, Phase IV platform trial of immunomodulatory therapies in patients with late stage 1 or stage 2 COVID-19-related disease, with a diagnosis based either on a positive assay or high suspicion of COVID-19 infection by clinical and/or radiological assessment.ParticipantsPatients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without ...
Source: Trials - Category: Research Source Type: clinical trials
Coronavirus disease 2019 (COVID-19) patients are at high risk of thrombosis related to endothelium injury, low blood flow and marked hypercoagulability [1]. Recently, a high prevalence of lupus anticoagulant (LA) was reported in the COVID-19 patients [2], immediately questioned by the possibility of false positive testing given the marked elevation in C-reactive protein (CRP) levels attributed to the major pulmonary or systemic inflammation in these patients [3]. Interestingly, a strong association between thrombosis and the presence of LA in critically ill COVID-19 was suggested but not demonstrated [4].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
As coronavirus 2019 (COVID-19) expands globally, its clinical heterogeneity has become increasingly apparent. In addition to varying presentations of respiratory failure and Acute Respiratory Distress Syndrome (ARDS), patients infected with the SARS-CoV-2 virus are also observed to have an increased incidence of thrombotic complications [1]. Autopsy reports performed on patients with severe COVID-19 support these findings, demonstrating intra-alveoloar fibrin deposition, endothelial injury, and wide-spread thrombosis with microangiopathy without obvious hyaline membrane formation or neutrophilic invasion seen commonly in o...
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
Roberts S, Rogan C, Schul MW, Komlos P, Stirling A, Thibault S, Varghese R, Welch HJ, Wittens CH Abstract The coronavirus disease 2019 (COVID-19) global pandemic has resulted in diversion of healthcare resources to the management of patients infected with SARS-CoV-2 virus. Elective interventions and surgical procedures in most countries have been postponed and operating room resources have been diverted to manage the pandemic. The Venous and Lymphatic Triage and Acuity Scale was developed to provide an international standard to rationalise and harmonise the management of patients with venous and lymphatic disorde...
Source: Phlebology - Category: Internal Medicine Authors: Tags: Phlebology Source Type: research
The coronavirus disease 2019 (COVID-19) outbreak caused by the novel coronavirus (SARS-CoV-2), which originated in Wuhan (China), has now spread across the globe affecting millions of people worldwide.1 COVID-19 is a hypercoagulable state and may lead to both venous and arterial thromboembolic events.2 This state is more common in cancer patients owing to an immunosuppressed state.3 Therefore, a thorough evaluation of the vascular system is warranted in these patients.
Source: Surgery - Category: Surgery Authors: Source Type: research
ConclusionsSince COVID-19 patients are at increased risk for arterial occlusion, it appears advisable to meticulously check for adequacy of collateral (hand-) perfusion, avoiding the harm of hand ischemia if interventions (e.g., catheterizations) at the radial or ulnar artery are intended.
Source: Journal of Clinical Monitoring and Computing - Category: Information Technology Source Type: research
More News: COVID-19 | General Medicine | Thrombosis